PDCD1 and cancer: As such, modulation of PD-1 and TIM-3 in cancer patients and the impact of inhibiting these molecules on γδ T cells is a point for consideration, as these immunotherapy drugs may deleteriously increase IL-17A expression and immunosuppressive neutrophil activation.